Terumo Neuro Presents Outstanding Data for New SOFIA™ Flow 88 Catheter at ESMINT Congress
Terumo Neuro, a prominent name in neurovascular innovation and part of Terumo Corporation, has made waves in the medical field with its recent presentation at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress. At this significant event, the company unveiled new real-world data demonstrating the efficacy of their latest device, the SOFIA Flow 88 Neurovascular Aspiration Catheter.
This cutting-edge catheter has shown promising results compared to its predecessors and competitors, marking a considerable advancement in thrombectomy procedures. Based on data gathered from 70 procedures performed across 16 hospitals in the EMEA region, the findings illustrate a notable preference among physicians for the SOFIA Flow 88.
An astonishing 83% of the physicians involved in the study confirmed that the SOFIA Flow 88 reliably reached the target location during procedures, even in complex anatomies, with 76% occurring in the internal carotid artery terminus (ICA-T) or beyond. Furthermore, the ease of use of the catheter was recognized by all participating physicians, as they rated it 'Same' or 'Better' than the previously preferred SOFIA Plus 6F in terms of trackability, ensuring precise navigation to the target vessel location.
Overall satisfaction with the performance of the SOFIA Flow 88 was high, with 92% of physicians responding that it performed 'Same', 'Better', or 'Much Better' than other available aspiration catheters. These results suggest that the SOFIA Flow 88 is not only efficient but also enhances the procedural experience for medical professionals dealing with acute stroke patients.
Carsten Schroeder, President and CEO of Terumo Neuro, showcased the SOFIA Flow 88 as a significant evolution in mechanical thrombectomy therapy. He emphasized the catheter's innovative super bore design which maximizes aspiration capabilities while minimizing flow disruption. This feature is vital to ensure that physicians can navigate through tortuous vascular pathways efficiently and with reduced risk to the patient.
The SOFIA Flow 88 catheter was launched commercially in the EMEA on June 2, 2025. Designed for optimal trackability, stability, and vessel-friendly flexibility, it integrates seamlessly into various aspiration strategies, providing physicians with enhanced control during procedures.
The data revealed at ESMINT underscores previous findings from U.S. studies and the European SESAME Study, which collectively established the safety and effectiveness of the SOFIA catheter line as a frontline choice in mechanical thrombectomy.
In addition to the SOFIA Flow 88, Terumo Neuro's comprehensive stroke solution includes the ERIC Retrieval Device for thrombus control and procedural flexibility, the BOBBY Balloon Guide Catheter, which employs next-generation balloon technology for reliable flow arrest, and TRAXCESS Guidewires designed for the toughest anatomies. All these elements work in harmony to support healthcare providers in delivering effective treatment for patients experiencing strokes.
Founded in 1997 and acquired by Terumo in 2006, Terumo Neuro is dedicated to innovation in neurovascular treatment. With a broad portfolio exceeding thirty products aimed at addressing cerebral aneurysms, ischemic strokes, and related conditions, the company remains at the forefront of advancements in the medical field. For more information about Terumo Neuro and their tools for enhancing patient outcomes, visit www.terumoneuro.com.
This cutting-edge catheter has shown promising results compared to its predecessors and competitors, marking a considerable advancement in thrombectomy procedures. Based on data gathered from 70 procedures performed across 16 hospitals in the EMEA region, the findings illustrate a notable preference among physicians for the SOFIA Flow 88.
An astonishing 83% of the physicians involved in the study confirmed that the SOFIA Flow 88 reliably reached the target location during procedures, even in complex anatomies, with 76% occurring in the internal carotid artery terminus (ICA-T) or beyond. Furthermore, the ease of use of the catheter was recognized by all participating physicians, as they rated it 'Same' or 'Better' than the previously preferred SOFIA Plus 6F in terms of trackability, ensuring precise navigation to the target vessel location.
Overall satisfaction with the performance of the SOFIA Flow 88 was high, with 92% of physicians responding that it performed 'Same', 'Better', or 'Much Better' than other available aspiration catheters. These results suggest that the SOFIA Flow 88 is not only efficient but also enhances the procedural experience for medical professionals dealing with acute stroke patients.
Carsten Schroeder, President and CEO of Terumo Neuro, showcased the SOFIA Flow 88 as a significant evolution in mechanical thrombectomy therapy. He emphasized the catheter's innovative super bore design which maximizes aspiration capabilities while minimizing flow disruption. This feature is vital to ensure that physicians can navigate through tortuous vascular pathways efficiently and with reduced risk to the patient.
The SOFIA Flow 88 catheter was launched commercially in the EMEA on June 2, 2025. Designed for optimal trackability, stability, and vessel-friendly flexibility, it integrates seamlessly into various aspiration strategies, providing physicians with enhanced control during procedures.
The data revealed at ESMINT underscores previous findings from U.S. studies and the European SESAME Study, which collectively established the safety and effectiveness of the SOFIA catheter line as a frontline choice in mechanical thrombectomy.
In addition to the SOFIA Flow 88, Terumo Neuro's comprehensive stroke solution includes the ERIC Retrieval Device for thrombus control and procedural flexibility, the BOBBY Balloon Guide Catheter, which employs next-generation balloon technology for reliable flow arrest, and TRAXCESS Guidewires designed for the toughest anatomies. All these elements work in harmony to support healthcare providers in delivering effective treatment for patients experiencing strokes.
Founded in 1997 and acquired by Terumo in 2006, Terumo Neuro is dedicated to innovation in neurovascular treatment. With a broad portfolio exceeding thirty products aimed at addressing cerebral aneurysms, ischemic strokes, and related conditions, the company remains at the forefront of advancements in the medical field. For more information about Terumo Neuro and their tools for enhancing patient outcomes, visit www.terumoneuro.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.